ORLANDO, Fla. An investigational treatment for Type 2 diabetes by Boehringer Ingelheim Pharmaceuticals significantly lowered blood sugar, according to results of a late-stage clinical study presented at a scientific meeting.
The drug maker announced Saturday the presentation of data from a phase 3 study of the once-daily pill linagliptin, saying that the drug achieved statistically significant and sustained reductions in blood sugar, according to standard measures. The results were presented at the 70th annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.
“It is imperative that blood sugar levels in people with Type 2 diabetes are adequately controlled,” Boehringer Ingelheim Pharmaceuticals executive director and medical leader for medical affairs in cardiovascular and metabolic medicine Giora Davidai said in a statement. “Uncontrolled blood sugar puts Type 2 diabetes patients at a higher risk of developing serious complications like renal impairment and cardiovascular disease, which are very common in patients with Type 2 diabetes.”